Clinical trials
Recruiting Multiple Sclerosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
133 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 5 |
| 2017 | 7 |
| 2018 | 2 |
| 2019 | 4 |
| 2021 | 9 |
| 2022 | 6 |
| 2023 | 15 |
| 2024 | 19 |
| 2025 | 38 |
| 2026 | 21 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 133 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Institute of Neurological Disorders and Stroke (NINDS) | 5 |
| University of Illinois at Chicago | 5 |
| Brigham and Women's Hospital | 4 |
| Novartis Pharmaceuticals | 4 |
| University of California, San Francisco | 4 |
| University of Washington | 4 |
| Bristol-Myers Squibb | 3 |
| Hunter College of City University of New York | 3 |
| Icahn School of Medicine at Mount Sinai | 3 |
| Johns Hopkins University | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 133 |
| Multiple Sclerosis, Chronic Progressive | 14 |
| Multiple Sclerosis, Relapsing-Remitting | 13 |
| Alzheimer Disease | 7 |
| Spinal Cord Injuries | 7 |
| Cognitive Dysfunction | 6 |
| Fatigue | 6 |
| Parkinson Disease | 6 |
| Stroke | 6 |
| Amyotrophic Lateral Sclerosis | 5 |
Trials
Showing 1 to 25 of 133. Each trial links to its page on Pharma Observatory.
33 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.